We performed a phase II study of a novel combination of AR-targeting agents in patients with clinically localized prostate cancer at high risk of disease recurrence and, despite biochemical responses in all patients, observed significant variability in measured tumor response. The gene discussed is AR; the disease is prostate carcinoma.